The high BCL2 group showed superior disease-free survival compared with the low BCL2 group ( p = 0.002), especially regarding local recurrence-free survival ( p = 0.045) and systemic recurrence-free survival ( p = 0.002). BCL1 expression revealed no impact on survival. The Cox proportional hazards model was used to calculate hazard ratio (HR) and the 95% confidence interval (CI) of survival analyses. The Kaplan–Meier estimator and log-rank test were used for survival analyses. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |